Provided herein are compositions and methods comprising immunogenic polypeptides related to the prevention and treatment of Epstein Ban vims infection and related pathologies.

Methods of generating an isolated population of non-graft versus host disease (GVHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, are disclosed. Cells generated by the methods, pharmaceutical compositions and methods of treatment are also disclosed.

The disclosure relates to a method for inducing antigen-specific T cell and the use thereof in treating cancer or virus infection. The method comprises culturing PBMCs with antigenic peptide, IL-2, IL-15 and IFN-.

The invention described herein provide Kaposi Sarcoma-Associated Herpesvirus (KSHV) oncoprotein antigens and epitopes for expanding antigen-specific T cells. Such expanded T cells are useful for, e.g., in allogeneic or off-the-shelf adoptive T cell therapy.

The present invention provides a T cell receptor (TCR) capable of specifically binding to HPV 16 E6 antigen short peptide complex TIHDIILECV-HLA A0201. Moreover, an effector cell transducing the TCR of the present disclosure also has a strong killing function. Such TCR can be used separately or in combination with other therapeutic agents, and can also be used in adoptive cellular immunotherapy to target a tumor cell presenting the complex TIHDIILECV-HLA A0201.

The present invention relates to modified immune cells or precursors thereof, comprising dual (a first and a second) chimeric receptors (e.g. CARs). One aspect includes a first CAR comprising a 4-1BB intracellular domain and a second CAR comprising a CD28 intracellular domain. Another aspect includes a method for treating of an HIV infected mammal using a modified T cell comprising a first CD4 CAR comprising a 4-1BB intracellular domain and a second CD4 CAR comprising a CD28 intracellular domain.

An engineered immune cell comprising a first functional exogenous receptor capable of binding and depleting natural killer (NK) cells, and a second functional exogenous receptor, wherein the engineered immune cell has reduced MHC I on cell surface.

Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a NPM 1 positive haematological malignancy. Corresponding methods and uses are also provided.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Provided are CAR-T compositions that are directed to HLA-DR. Certain provided HLA-DR CAR compositions exhibit low affinity for a polymorphic region of HLA-DR of a subject. Various in vitro and in vivo methods and reagents related to HLA-DR CAR-T are also provided. Methods described herein can include, for example, characterization of HLA-DR binding, proliferation of T-cells, as well as prevention and/or therapeutic treatment of cancer using a HLA-DR CAR-T composition provided herein.